Our History

CivaTech Oncology Inc., a corporation located in Research Triangle Park, North Carolina, was founded in 2006. CivaTech Oncology offers cancer patients radiation therapy treatment options that minimize distress and inconvenience, maximize quality of life and improve life expectancy. The Company developed and is commercializing innovative polymer-based low-dose rate (LDR) brachytherapy devices, pioneering a new standard of care in treatment of various stages of cancer.

Meet Our Team

Suzanne Babcock
Suzanne Babcock
Executive Chairman and CEO
Randy Harrison
Randy Harrison
National Sales Manager
Kristy Perez, PhD
VP of Clinical Programs
Mark J. Rivard, PhD
Mark J. Rivard, PhD
Chief Science Officer
George Paschal MD
George Paschal MD
Chief Medical Officer

Product History

Our first product, called the CivaString®, has been cleared by the FDA for use in localized solid tumors or residual disease, and the product began use to treat prostate cancers in 2013. The Company’s second product, is a bioabsorbable, planar sheet called the CivaSheet®, received FDA clearance in 2014 and is the first commercially available brachytherapy device that has integrated radiation shielding built into the implantable device, making it more safe and allowing broader applications where previously risk of harming healthy tissue was problematic.

Both products are customized for the patient and the strengths can be varied according to the prescription. CivaTech Oncology’s products are significantly more accurate to prescription than traditional metal encapsulated seeds.

Contact Us